April 20, 2024

Medical Trend

Medical News and Medical Resources

AstraZeneca COVID-19 vaccine Vaxzevria approved in Japan

AstraZeneca COVID-19 vaccine Vaxzevria approved in Japan: for people 18 years and older!


AstraZeneca COVID-19 vaccine Vaxzevria approved in Japan.  Recently, AstraZeneca announced that its COVID-19 vaccine Vaxzevria (ChAdOx1-S [recombinant], formerly known as AZD1222) has been approved for emergency use in Japan for active immunization of people aged 18 and over. Prevent the new type of coronavirus pneumonia (COVID-19) caused by the new type of coronavirus (SARS-CoV-2).

Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Vaxzevria, based on the positive efficacy and safety of the Phase 3 clinical trial in the clinical trial project led by Oxford University in the United Kingdom, Brazil and South Africa, and the Phase I/II clinical trial conducted in Japan Sexual data.

The Pharmaceuticals and Medical Devices Agency of Japan (PMDA) recommends that the use of Vaxzevria should be limited to adults, and given by intramuscular injection, two 0.5 ml doses, with an interval of 4 to 12 weeks, with an interval of more than 8 weeks, in order to maximize its effectiveness. . Clinical trials have shown that the vaccination program is well tolerated and can effectively prevent symptomatic COVID-19. There were no serious cases and hospitalizations 14 days after the second vaccination.

Mene Pangalos, executive vice president of AstraZeneca Biopharmaceuticals R&D, said: “We continue to expand access to vaccines globally. Today’s approval brings us one step closer to providing COVID-19 vaccines to Japanese people who desperately need protection. We are Proud to produce a vaccine for the world, which is playing a leading role in the global fight against the COVID-19 pandemic. AstraZeneca and sub-licensees are currently available to 165 countries around the world More than 400 million doses of vaccine.”

In Japan, Vaxzevria vaccine production is already underway, and the first batch of vaccines is expected to be available in the next few weeks.

So far, the vaccine has obtained conditional sales licenses or emergency use in more than 80 countries on six continents, and has been included in the World Health Organization (WHO) emergency use list, which has accelerated the use of COVAX facilities in as many as 142 The country’s access to vaccines.

Vaxzevria (ChAdOx1-S[recombination], formerly known as AZD1222) was co-invented by Oxford University and its spin-off company Vaccitech. It uses a replication-deficient chimpanzee virus vector based on a weakened version of the common cold virus (adenovirus), which causes infection in chimpanzees and contains the genetic material of the spike protein of the SARS-CoV-2 virus. After vaccination, a surface spike protein is produced, which stimulates the immune system to attack the SARS-CoV-2 virus.

Vaxzevria can be stored, transported and handled under conventional refrigeration conditions (2-8°C/36-46°F) for at least 6 months, and can be used in existing medical environments.

AstraZeneca continues to work with governments, international organizations and partners around the world to ensure widespread and fair access to vaccines during the COVID-19 pandemic, without any profit.


(source:internet, reference only)

Disclaimer of medicaltrend.org